Cognito's $105 million Series C will advance their pivotal FDA study, expand clinical neurology partnerships, and expand work past Alzheimer's into Parkinsons and beyond.
Cognito Therapeutics Announces Oversubscribed $105 Million Series C Financing to Advance Spectris™ in Alzheimer’s Disease ...
Medical Device Network on MSN
Cognito Therapeutics raises $105M for Alzheimer’s therapeutic advancement
With a pivotal trial readout for Cognito’s Spectris due later this year, the company anticipates launching the Alzheimer’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results